Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Emerging evidence suggests a potential association between elevated body mass index (BMI) and enhanced ICI efficacy, yet this relationship remains inconclusive and warrants further investigation. This study aims to evaluate the impact of BMI on treatment efficacy and survival outcomes in advanced NSCLC patients treated with first-line ICI therapy.

Methods

A retrospective study was conducted at a multi-center registry to evaluate the impact of baseline BMI on overall survival (OS) and progression-free survival (PFS) in patients with stage IV NSCLC who received first-line ICI therapies. Treatment regimens included pembrolizumab or the combination of

SUBMITTER: Shalata W 

PROVIDER: S-EPMC11988004 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature